Thus, we must fully characterize which GLP-1 sites of action mediate nausea/emesis to best develop obesity pharmacotherapies that maintain their therapeutic potential with minimal side effects. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.